Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA3 | P07451 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17241030 | 0.89 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL692195 | 0.84 | LMNA (0.58) | LMNACA12CA1CA2CA3 | |
| SCHEMBL29361971 | 0.84 | LMNA (0.58) | LMNACA12CA1CA2CA3 | |
| SCHEMBL3563801 | 0.81 | LMNA (0.54) | LMNACA12CA1CA2CA3 | |
| SCHEMBL31061939 | 0.81 | LMNA (0.59) | LMNACA12CA1CA2CA3 | |
| SCHEMBL6993416 | 0.81 | LMNA (0.54) | LMNACA12CA1CA2CA3 | |
| SCHEMBL12767421 | 0.81 | LMNA (0.59) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1560932 | 0.81 | LMNA (0.54) | LMNACA12CA1CA2CA3 | |
| SCHEMBL6714180 | 0.81 | LMNA (0.54) | LMNACA12CA1CA2CA3 | |
| SCHEMBL5511869 | 0.78 | LMNA (0.51) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024018403-A1 | SUBSTITUTED IMIDAZOAMIDE COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-01-25 | — | — | WO | disclosed |
| EP-3140295-B1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-09-12 | — | — | EP | disclosed |
| US-9809598-B2 | Heterocyclyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| EP-3140295-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2017-03-15 | — | — | EP | disclosed |
| CN-105399697-A | Amino sulfonyl compound, preparation method and uses thereof | SUZHOU WANGSHAN WANGSHUI BIOMEDICAL CO LTD | 2016-03-16 | — | — | CN | disclosed |
| WO-2015169421-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-11-12 | — | — | WO | disclosed |
| US-20150031686-A1 | PHENYL-OXAZOLYL DERIVATIVES, PREPARATION METHOD THEREOF, AND RELATED APPLICATION OF THE PHENYL-OXAZOLYL DERIVATIVES AS AN IMPDH INHIBITOR | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2015-01-29 | — | — | US | disclosed |
| CN-103889976-A | Indazole compounds, compositions and methods of use | HOFFMANN LA ROCHE | 2014-06-25 | — | — | CN | disclosed |
| EP-0789692-A1 | BENZISOXAZOLE DERIVATIVES AND PESTICIDAL COMPOSITIONS CONTAINING THEM | Novartis AG (CH) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031686-A1 | PHENYL-OXAZOLYL DERIVATIVES, PREPARATION METHOD THEREOF, AND RELATED APPLICATION OF THE PHENYL-OXAZOLYL DERIVATIVES AS AN IMPDH INHIBITOR | IMPDH1, IMPDH2, IMPA1 | LMNA 2857/4885CA12 4824/4885CA1 4356/4885 |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | TNKS, TANK, TBKBP1 | LMNA 1777/4885CA12 3887/4885CA1 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.